MedTrace Logo

Plasma Exchanges in Multiple Sclerosis (MS) Relapses

NCT01442233 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2026-05-14

No results posted yet for this study

Summary

In more than 40 % of multiple sclerosis (MS) patients experiencing relapse, residual disability accumulates in spite of steroid treatment. Plasma exchanges are frequently used but there is no established evidence of their efficacy.

Conditions

Interventions

PROCEDURE

plasma exchange

6 plasma exchange each 48 hours during 2 weeks after randomization

PROCEDURE

sham exchanges procedure

6 sham exchanges each 48 hours during 2 weeks after randomization

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • Linda WITTKOP, MD PhD · university bordeaux hospital

  • Bruno BROCHET, MD · University Hospital Bordeaux, France

  • Bruno BROCHET, MD · University Hospital Bordeaux, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-08
Primary Completion
2017-09-21
Completion
2017-09-21

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01442233 on ClinicalTrials.gov